Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.

导出 LinkOut

翻译打印收藏纠错

第一作者： Danna,Jennings

第一单位： Denali Therapeutics Inc., South San Francisco, CA, USA.

作者： Danna,Jennings ^[1] ; Sarah,Huntwork-Rodriguez ^[1] ; Anastasia G,Henry ^[1] ; Jennifer C,Sasaki ^[1] ; René,Meisner ^[1] ; Dolores,Diaz ^[1] ; Hilda,Solanoy ^[1] ; Xiang,Wang ^[1] ; Elvira,Negrou ^[1] ; Vitaliy V,Bondar ^[2] ; Rajarshi,Ghosh ^[1] ; Michael T,Maloney ^[1] ; Nicholas E,Propson ^[1] ; Yuda,Zhu ^[1] ; Romeo D,Maciuca ^[1] ; Laura,Harris ^[1] ; Angela,Kay ^[1] ; Peter,LeWitt ^[3] ; T Alex,King ^[4] ; Drew,Kern ^[5] ; Aaron,Ellenbogen ^[6] ; Ira,Goodman ^[7] ; Andrew,Siderowf ^[8] ; Jason,Aldred ^[9] ; Omid,Omidvar ^[10] ; Shababa T,Masoud ^[1] ; Sonnet S,Davis ^[1] ; Annie,Arguello ^[1] ; Anthony A,Estrada ^[1] ; Javier,de Vicente ^[1] ; Zachary K,Sweeney ^[11] ; Giuseppe,Astarita ^[1] ; Marie T,Borin ^[3] ; Bradley K,Wong ^[1] ; Harvey,Wong ^[1] ; Hoang,Nguyen ^[12] ; Kimberly,Scearce-Levie ^[1] ; Carole,Ho ^[1] ; Matthew D,Troyer ^[1]

作者单位： Denali Therapeutics Inc., South San Francisco, CA, USA. ^[1] REGENXBIO, Rockville, MD, USA. ^[2] Henry Ford Health System, Detroit, MI, USA. ^[3] Covance, Dallas, TX, USA. ^[4] University of Colorado, School of Medicine, Aurora, CO, USA. ^[5] Michigan Institute for Neurological Disorders, Farmington Hills, MI, USA. ^[6] Bioclinica Research, Orlando, FL, USA. ^[7] University of Pennsylvania, Penn Neurology Pennsylvania Hospital, Philadelphia, PA, USA. ^[8] Inland Northwest Research, Spokane, WA, USA. ^[9] Collaborative Neuroscience Research, Long Beach, CA, USA. ^[10] Interline Therapeutics, South San Francisco, CA, USA. ^[11] University of British Columbia, Vancouver, BC, Canada. ^[12]